WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, December 03, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L13	Wettendorff.in.	2
		DB=EPAB; PLUR=YES; OP=ADJ	
☐	L12	AU-2003293942-A1.did.	0
☐	L11	WO-200117551-A2.did.	0
☐	L10	AU-2003236490-B2.did.	0
☐	L9	EP-1210113-A2.did.	0
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L8	Wettendorff.in.	2
		DB=EPAB; PLUR=YES; OP=ADJ	
☐	L7	WO-2004056389-A1.did.	1
☐	L6	WO-2004056389-A1.did.	1
		DB=DWPI; PLUR=YES; OP=ADJ	
☐	L5	Wettendorff.in.	6
☐	L4	3DMPL	0
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L3	3DMPL	11
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L2	3DMPL	5
☐	L1	3D-MPL	104

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: AU 2003293942 A1, WO 2004056389 A1

L5: Entry 1 of 6 File: DWPI Jul 14, 2004

DERWENT-ACC-NO: 2004-500265
DERWENT-WEEK: 200474
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: A composition comprising human papilloma virus (HPV) 16 and HPV 18 virus-like particles (VLPs), useful in preparing a medicament for preventing infection caused by one or more oncogenic HPV types, excluding types HPV 16 and HPV 18

INVENTOR: DUBIN, G; INNIS, B ; SLAOUI, M M ; WETTENDORFF, M A C

PRIORITY-DATA: 2003US-496653P (August 20, 2003), 2002US-435035P (December 20, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003293942 A1	July 14, 2004		000	A61K039/12
WO 2004056389 A1	July 8, 2004	E	033	A61K039/12

INT-CL (IPC): A61 K 39/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | [illegible] | [illegible] | Claims | KWIC | Draw De

☐ 2. Document ID: AU 2003218787 A1, WO 2003077942 A2

L5: Entry 2 of 6 File: DWPI Sep 29, 2003

DERWENT-ACC-NO: 2003-779087
DERWENT-WEEK: 200432
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: New vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 or HPV 45 genotypes, useful for preventing or treating HPV infection or cervical cancer

INVENTOR: WETTENDORFF, M A C

PRIORITY-DATA: 2002GB-0006360 (March 18, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003218787 A1	September 29, 2003		000	A61K039/12
WO 2003077942 A2	September 25, 2003	E	033	A61K039/12

INT-CL (IPC): A61 K 39/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 3. Document ID: AU 2003236490 B2, WO 200117551 A2, AU 200077751 A, BR 200014171 A, EP 1210113 A2, NO 200201116 A, CZ 200200843 A3, KR 2002027630 A, HU 200202804 A2, JP 2003508495 W, CN 1387443 A, NZ 517621 A, MX 2002002484 A1, NO 200303715 A, AU 766494 B, CA 2443214 A1, JP 2004067696 A, KR 2003087081 A, AU 2003236490 A1, EP 1410805 A1, ZA 200201810 A, US 20040126394 A1, ZA 200306402 A

L5: Entry 3 of 6 File: DWPI Aug 19, 2004

DERWENT-ACC-NO: 2001-226727
DERWENT-WEEK: 200474

TITLE: Vaccine composition comprising a herpes simplex virus antigen and a human papillomavirus antigen, useful in the treatment or prophylaxis of human papillomavirus infections and herpes simplex virus infections

INVENTOR: WETTENDORFF, M A C; WETTENDORFF, M

PRIORITY-DATA: 1999GB-0021146 (September 7, 1999), 2003AU-0236490 (August 27, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003236490 B2	August 19, 2004		000	A61K039/00
WO 200117551 A2	March 15, 2001	E	042	A61K039/00
AU 200077751 A	April 10, 2001		000	A61K039/00
BR 200014171 A	May 21, 2002		000	A61K039/00
EP 1210113 A2	June 5, 2002	E	000	A61K039/295
NO 200201116 A	April 30, 2002		000	A61K000/00
CZ 200200843 A3	August 14, 2002		000	A61K039/00
KR 2002027630 A	April 13, 2002		000	A61K039/295
HU 200202804 A2	December 28, 2002		000	A61K039/295
JP 2003508495 W	March 4, 2003		044	A61K039/23
CN 1387443 A	December 25, 2002		000	A61K039/295
NZ 517621 A	September 26, 2003		000	A61K039/295
MX 2002002484 A1	September 1, 2002		000	A61K039/295
NO 200303715 A	April 30, 2002		000	A61K039/12
AU 766494 B	October 16, 2003		000	A61K039/00
CA 2443214 A1	March 15, 2001	E	000	A61K039/39
JP 2004067696 A	March 4, 2004		023	A61K039/23
KR 2003087081 A	November 12, 2003		000	A61K039/295
AU 2003236490 A1	September 18, 2003		000	A61K039/00
EP 1410805 A1	April 21, 2004	E	000	A61K039/295
ZA 200201810 A	May 26, 2004		059	A61K000/00
US 20040126394 A1	July 1, 2004		000	A61K039/295
ZA 200306402 A	October 27, 2004		040	A61K000/00

766494 B , CA 2443214 A1 , JP 2004067696 A INT-CL (IPC): A61 K 0/00; A61 K 39/00; A61 K 39/002; A61 K 39/12; A61 K 39/23; A61 K 39/245; A61 K 39/25; A61 K 39/29; A61 K 39/295; A61 K 39/39; A61 P 31/12; A61 P 31/20; A61 P 31/22; A61 P 35/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 4. Document ID: ZA 200201834 A, WO 200117550 A2, AU 200072848 A, EP 1210112 A2, NO 200201115 A, BR 200014172 A, CZ 200200842 A3, KR 2002027629 A, HU 200202826 A2, JP 2003508494 W, CN 1390136 A, NZ 517622 A, AU 765245 B, MX 2002002483 A1

L5: Entry 4 of 6 File: DWPI Apr 28, 2004

DERWENT-ACC-NO: 2001-218537
DERWENT-WEEK: 200432
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Vaccine composition useful for combating papillomavirus infection, especially cervical cancer, comprises a hepatitis B viral antigen and a human papillomavirus antigen in conjunction with an adjuvant

INVENTOR: WETTENDORFF, M A C; WTTENDORFF, M A C

PRIORITY-DATA: 1999GB-0021147 (September 7, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ZA 200201834 A	April 28, 2004		062	A61K000/00
WO 200117550 A2	March 15, 2001	E	046	A61K039/00
AU 200072848 A	April 10, 2001		000	A61K039/00
EP 1210112 A2	June 5, 2002	E	000	A61K039/295
NO 200201115 A	April 30, 2002		000	A61K000/00
BR 200014172 A	May 14, 2002		000	A61K039/00
CZ 200200842 A3	August 14, 2002		000	A61K039/12
KR 2002027629 A	April 13, 2002		000	A61K039/295
HU 200202826 A2	December 28, 2002		000	A61K039/295
JP 2003508494 W	March 4, 2003		054	A61K039/29
CN 1390136 A	January 8, 2003		000	A61K039/295
NZ 517622 A	September 26, 2003		000	A61K039/395
AU 765245 B	September 11, 2003		000	A61K039/00
MX 2002002483 A1	September 1, 2002		000	A61K039/295

INT-CL (IPC): A61 K 0/00; A61 K 31/20; A61 K 39/00; A61 K 39/002; A61 K 39/12; A61 K 39/29; A61 K 39/295; A61 K 39/39; A61 K 39/395; A61 P 31/12; A61 P 31/20; A61 P 31/22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 5. Document ID: NZ 512890 A, WO 200041463 A2, AU 200021009 A, NO 200103337 A, EP 1140163 A2, BR 9916893 A, CZ 200102544 A3, KR 2001090011 A, HU 200105070 A2, ZA 200105690 A, MX 2001007112 A1, JP 2002534438 W, CN 1391482 A, AU 760574 B

L5: Entry 5 of 6 File: DWPI Sep 26, 2003

DERWENT-ACC-NO: 2000-490988
DERWENT-WEEK: 200366

TITLE: Treatment and prevention of hepatitis B virus infection, using an antiviral agent and a vaccine in simultaneous or sequential use

INVENTOR: ATKINSON, G F; BOON, R J ; VANDEPAPELIERE, P G ; WETTENDORFF, M A C

PRIORITY-DATA: 1999GB-0000630 (January 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
NZ 512890 A	September 26, 2003		000	A61K039/29
WO 200041463 A2	July 20, 2000	E	018	A61K031/52
AU 200021009 A	August 1, 2000		000	A61K031/00
NO 200103337 A	August 17, 2001		000	A61K000/00
EP 1140163 A2	October 10, 2001	E	000	A61K039/29
BR 9916893 A	November 20, 2001		000	A61K031/00
CZ 200102544 A3	January 16, 2002		000	A61K009/20
KR 2001090011 A	October 17, 2001		000	A61K031/70
HU 200105070 A2	April 29, 2002		000	A61K031/00
ZA 200105690 A	September 25, 2002		042	A61K000/00
MX 2001007112 A1	November 1, 2001		000	A61K031/00
JP 2002534438 W	October 15, 2002		026	A61K045/00
CN 1391482 A	January 15, 2003		000	A61K039/29
AU 760574 B	May 15, 2003		000	A61K031/00

INT-CL (IPC): A61 J 1/03; A61 K 0/00; A61 K 9/20; A61 K 31/00; A61 K 31/513; A61 K 31/52; A61 K 31/522; A61 K 31/662; A61 K 31/70; A61 K 31/7052; A61 K 31/7056; A61 K 31/7076; A61 K 38/21; A61 K 39/00; A61 K 39/29; A61 K 39/39; A61 K 45/00; A61 P 1/16; A61 P 5/00; A61 P 31/20; C12 N 0/00

☐ 6. Document ID: TW 580393 A, WO 9945957 A2, AU 9933283 A, NO 200004487 A, BR 9908599 A, EP 1064025 A2, ZA 9901829 A, CZ 200003284 A3, HU 200101047 A2, CN 1299288 A, KR 2001041629 A, MX 2000008817 A1, JP 2002506045 W, AU 750720 B, US 6451320 B1, NZ 506602 A, US 20030129199 A1

L5: Entry 6 of 6 File: DWPI Mar 21, 2004

DERWENT-ACC-NO: 1999-551216
DERWENT-WEEK: 200458

TITLE: New vaccine compositions containing a hepatitis B viral antigen, a herpes simplex viral antigen and an adjuvant which is a preferential stimulator of a TH1 cell response

INVENTOR: STEPHENNE, J; WETTENDORFF, M A C

PRIORITY-DATA: 1998GB-0013561 (June 23, 1998), 1998GB-0005105 (March 9, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
TW 580393 A	March 21, 2004		000	A61K039/295
WO 9945957 A2	September 16, 1999	E	038	A61K039/295
AU 9933283 A	September 27, 1999		000	A61K039/295
NO 200004487 A	October 19, 2000		000	A61K000/00
BR 9908599 A	November 14, 2000		000	A61K039/295
EP 1064025 A2	January 3, 2001	E	000	A61K039/295
ZA 9901829 A	November 29, 2000		037	A61K000/00
CZ 200003284 A3	February 14, 2001		000	A61K039/295
HU 200101047 A2	July 30, 2001		000	A61K039/295
CN 1299288 A	June 13, 2001		000	A61K039/295
KR 2001041629 A	May 25, 2001		000	A61K039/295
MX 2000008817 A1	March 1, 2001		000	A61K039/295
JP 2002506045 W	February 26, 2002		047	A61K039/295
AU 750720 B	July 25, 2002		000	A61K039/295
US 6451320 B1	September 17, 2002		000	A61K039/295
NZ 506602 A	February 28, 2003		000	A61K039/295
US 20030129199 A1	July 10, 2003		000	A61K039/295

506602 A , US 20030129199 A1 INT-CL (IPC): A61 K 0/00; A61 K 39/00; A61 K 39/02; A61 K 39/12; A61 K 39/245; A61 K 39/25; A61 K 39/29; A61 K 39/295; A61 K 39/385; A61 K 39/39; A61 K 39/42; A61 P 31/12; A61 P 37/00; C07 K 14/02; C07 K 14/03

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
Wettendorff.in.	6

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

L2 ANSWER 1 OF 9 MEDLINE on STN
AN 2003457800 MEDLINE
DN PubMed ID: 14520455
TI Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.
AU Wang S S; Schiffman M; Shields T S; Herrero R; Hildesheim A; Bratti M C; Sherman M E; Rodriguez A C; Castle P E; Morales J; Alfaro M; Wright T; Chen S; Clayman B; Burk R D; Viscidi R P
CS National Cancer Institute, Bethesda, MD 20892-7234, USA.. wangso@mail.nih.gov
NC N01CP21081 (NCI)
N01PP31061
R01CA78527 (NCI)
SO British journal of cancer, (2003 Oct 6) 89 (7) 1248-54.
Journal code: 0370635. ISSN: 0007-0920.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200311
ED Entered STN: 20031002
Last Updated on STN: 20031218
Entered Medline: 20031125
AB Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on **VLP**-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for **HPV-16** (n=9949), **HPV-18** (n=9928), HPV-31 (n=9932), and HPV-45 (n=3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n=573). **HPV-16**, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for **HPV-16**, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.
CT Check Tags: Comparative Study; Female; Human; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.
Adolescent
Adult
Aged
Aged, 80 and over
*Antibodies, Viral: BL, blood
Antigens, Viral: IM, immunology
*Cervical Intraepithelial Neoplasia: EP, epidemiology
Cervical Intraepithelial Neoplasia: VI, virology
*Cervix Neoplasms: EP, epidemiology
Cervix Neoplasms: VI, virology
Cohort Studies
Costa Rica: EP, epidemiology
DNA, Viral: AN, analysis
Middle Aged
*Papillomavirus Infections: EP, epidemiology
Papillomavirus Infections: VI, virology
Papillomavirus, Human: GE, genetics
*Papillomavirus, Human: IM, immunology
Polymerase Chain Reaction
Seroepidemiologic Studies
CN 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (DNA, Viral)

L2 ANSWER 2 OF 9 MEDLINE on STN
AN 2001222330 MEDLINE
DN PubMed ID: 11312347
TI Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
AU Gerber S; Lane C; Brown D M; Lord E; DiLorenzo M; Clements J D; Rybicki E; Williamson A L; Rose R C
CS University of Rochester Medical Center, Rochester, New York 14642, USA.
NC CA 84105-01 (NCI)
SO Journal of virology, (2001 May) 75 (10) 4752-60.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 20010529
Last Updated on STN: 20010529
Entered Medline: 20010524
AB Certain human papillomaviruses (HPVs) cause most cervical cancer, which remains a significant source of morbidity and mortality among women worldwide. HPV recombinant virus-like particles (VLPs) are promising vaccine candidates for controlling anogenital HPV disease and are now being evaluated as a parenteral vaccine modality in human subjects. Vaccines formulated for injection generally are more costly, more difficult to administer, and less acceptable to recipients than are mucosally administered vaccines. Since oral delivery represents an attractive alternative to parenteral injection for large-scale human vaccination, the oral immunogenicity of HPV type 11 (HPV-11) VLPs in mice was previously investigated; it was found that a modest systemic neutralizing antibody response was induced (R. C. Rose, C. Lane, S. Wilson, J. A. Suzich, E. Rybicki, and A. L. Williamson, Vaccine 17:2129-2135, 1999). Here we examine whether VLPs of other genotypes may also be immunogenic when administered orally and whether mucosal adjuvants can be used to enhance **VLP** oral immunogenicity. We show that **HPV-16** and **HPV-18** VLPs are immunogenic when administered orally and that oral coadministration of these antigens with Escherichia coli heat-labile enterotoxin (LT) mutant R192G (LT R192G) or CpG DNA can significantly improve anti-**VLP** humoral responses in peripheral blood and in genital mucosal secretions. Our results also suggest that LT R192G may be superior to CpG DNA in this ability. These findings support the concept of oral immunization against anogenital HPV disease and suggest that clinical studies involving this approach may be warranted.
CT Check Tags: Female; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
*Adjuvants, Immunologic
Administration, Oral
Animals
Antibodies, Viral: BL, blood
Antibodies, Viral: CL, classification
Antibody Specificity
Bacterial Toxins: GE, genetics
*Bacterial Toxins: IM, immunology
*CpG Islands: IM, immunology
Enterotoxins: GE, genetics
*Enterotoxins: IM, immunology
*Escherichia coli
Immunoglobulin G: BL, blood
Immunoglobulin G: CL, classification

Mice
Mice, Inbred BALB C
Mutagenesis, Site-Directed
*Oncogene Proteins, Viral: IM, immunology
*Papillomavirus, Human: IM, immunology
*Vaccines, Synthetic: IM, immunology
Vagina: IM, immunology
*Viral Vaccines: IM, immunology
Virion: IM, immunology

CN 0 (Adjuvants, Immunologic); 0 (Antibodies, Viral); 0 (Bacterial Toxins); 0 (Enterotoxins); 0 (Immunoglobulin G); 0 (Oncogene Proteins, Viral); 0 (Vaccines, Synthetic); 0 (Viral Vaccines); 0 (enterotoxin LT); 0 (oncogene viral capsid protein, L1 human papillomavirus type 16)

L2 ANSWER 3 OF 9 MEDLINE on STN
AN 2001214728 MEDLINE
DN PubMed ID: 11166904
TI Immunological analyses of human papillomavirus capsids.
AU Giroglou T; Sapp M; Lane C; Fligge C; Christensen N D; Streeck R E; Rose R C
CS Institute for Medical Microbiology and Hygiene, University of Mainz, D-55101, Mainz, Germany.
SO Vaccine, (2001 Feb 8) 19 (13-14) 1783-93.
Journal code: 8406899. ISSN: 0264-410X.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200104
ED Entered STN: 20010425
Last Updated on STN: 20010425
Entered Medline: 20010419

AB Recombinant human papillomavirus (HPV) virus-like particles (VLPs) are promising vaccine candidates for controlling anogenital HPV disease. Questions remain, however, concerning the extent of capsid antigenic similarity between closely related virus genotypes. To investigate this issue, we produced VLPs and corresponding polyclonal immune sera from several anogenital HPV types, and examined these reagents in enzyme-linked immunosorbent assays (ELISAs) and in cross-neutralization studies. Despite varying degrees of L1 genetic sequence relatedness, VLPs of each type examined induced high-titer serum polyclonal antibody responses that were entirely genotype-specific. In an in vitro infectivity assay, only cognate **VLP** antisera were able to neutralize pseudovirions of **HPV-16**, **HPV-18** and HPV-33, with two exceptions: HPV-31 and HPV-45 **VLP** post-immune sera demonstrated low levels of neutralizing activity against pseudovirions of HPV-33 and **HPV-18**, respectively. In other experiments, epitopes shared between closely related types were found to be less immunogenic than, and antigenically distinct from, primary type-specific B-cell determinants of the viral capsid. In addition, results from epitope blocking experiments suggested a close correlation between primary type-specific capsid antigenic sites and virion neutralization. These findings support the view that papillomavirus genotypes denote unique viral serotypes, and suggest that a successful vaccine for these viruses will likely require the inclusion of VLPs of each serotype for which protection is desired.

CT Check Tags: Human; Support, Non-U.S. Gov't
Absorption
Antibodies, Monoclonal: IM, immunology
Antibodies, Viral: IM, immunology
*Antibody Specificity: IM, immunology
Antigens, Viral: GE, genetics

> d l3 1-11 ti

L3 ANSWER 1 OF 11 MEDLINE on STN
TI The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.

L3 ANSWER 2 OF 11 MEDLINE on STN
TI Therapeutic vaccination.

L3 ANSWER 3 OF 11 MEDLINE on STN
TI Activation of primary allogeneic CD8+ T cells by dendritic cells generated in vitro from CD34+ cord blood progenitor cells.

L3 ANSWER 4 OF 11 MEDLINE on STN
TI FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.

L3 ANSWER 5 OF 11 MEDLINE on STN
TI Anti-idiotype cancer vaccines: pre-clinical and clinical studies.

L3 ANSWER 6 OF 11 MEDLINE on STN
TI Modulation of cancer patients' immune responses by anti-idiotypic antibodies.

L3 ANSWER 7 OF 11 MEDLINE on STN
TI Functional mimicry of tumor-associated antigens by antiidiotypic antibodies.

L3 ANSWER 8 OF 11 MEDLINE on STN
TI Modulation of cancer patients' immune responses by administration of anti-idiotypic antibodies.

L3 ANSWER 9 OF 11 MEDLINE on STN
TI Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.

L3 ANSWER 10 OF 11 MEDLINE on STN
TI Specific detection of antibodies in cancer patients following immunotherapy with anti-idiotype.

L3 ANSWER 11 OF 11 MEDLINE on STN
TI Anti-idiotype immunization of cancer patients: modulation of the immune response.

=> d l5 1-5

L5 ANSWER 1 OF 5 MEDLINE on STN
AN 2003155985 MEDLINE
DN PubMed ID: 12674200
TI High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines.
AU Kumar K Sree; Srinivasan V; Toles Raymond E; Miner Venita L; Jackson William E; Seed Thomas M
CS Radiation Casualty Management Team, Armed Forces Radiobiology Research Institute, Bethesda, MD 20889, USA.. kumar@afrri.usuhs.mil
SO Journal of radiation research, (2002 Dec) 43 (4) 361-70.
Journal code: 0376611. ISSN: 0449-3060.
CY Japan
DT (EVALUATION STUDIES)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200304
ED Entered STN: 20030404
Last Updated on STN: 20030426
Entered Medline: 20030425

L5 ANSWER 2 OF 5 MEDLINE on STN
AN 2002640668 MEDLINE
DN PubMed ID: 12399191
TI The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
AU Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
CS Interdisciplinaire Dienst voor het Welzijn, IDEWE, Leuven, Belgium.
SO Vaccine, (2002 Nov 1) 20 (31-32) 3644-9.
Journal code: 8406899. ISSN: 0264-410X.
CY Netherlands
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200305
ED Entered STN: 20021026
Last Updated on STN: 20030531
Entered Medline: 20030530

L5 ANSWER 3 OF 5 MEDLINE on STN
AN 2002351230 MEDLINE
DN PubMed ID: 12057618
TI Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant.
AU Desombere Isabelle; Van der Wielen Marie; Van Damme Pierre; Stoffel Michel; De Clercq Norbert; Goilav Christian; Leroux-Roels Geert
CS Centre for Vaccinology, Ghent University Hospital, De Pintelaan 185 9000, Ghent, Belgium.
SO Vaccine, (2002 Jun 7) 20 (19-20) 2597-602.
Journal code: 8406899. ISSN: 0264-410X.
CY England: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals

EM 200211
ED Entered STN: 20020704
Last Updated on STN: 20021214
Entered Medline: 20021127

L5 ANSWER 4 OF 5 MEDLINE on STN
AN 2000113866 MEDLINE
DN PubMed ID: 10649617
TI A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
AU McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; Beddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J
CS Department of Virology, St Thomas' Hospital (UMDS), London, UK.
SO Vaccine, (2000 Jan 18) 18 (13) 1166-77.
Journal code: 8406899. ISSN: 0264-410X.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals; AIDS
EM 200003
ED Entered STN: 20000330
Last Updated on STN: 20000330
Entered Medline: 20000322

L5 ANSWER 5 OF 5 MEDLINE on STN
AN 1999345239 MEDLINE
DN PubMed ID: 10418898
TI The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
AU Moore A; McCarthy L; Mills K H
CS Department of Biology, National University of Ireland, Maynooth, Co. Kildare.
SO Vaccine, (1999 Jun 4) 17 (20-21) 2517-27.
Journal code: 8406899. ISSN: 0264-410X.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199908
ED Entered STN: 19990910
Last Updated on STN: 19990910
Entered Medline: 19990826

d l12 1-7

L12 ANSWER 1 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:212478 BIOSIS
DN PREV200300212478
TI High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines.
AU Kumar, K. Sree [Reprint Author]; Srinivasan, V.; Toles, Raymond E.; Miner, Venita L.; Jackson, William E.; Seed, Thomas M.
CS United States Military Cancer Institute, Washington, D.C., USA
kumar@afrri.usuhs.mil
SO Journal of Radiation Research, (December 2002) Vol. 43, No. 4, pp. 361-370. print.
CODEN: JRARAX. ISSN: 0449-3060.
DT Article
LA English
ED Entered STN: 30 Apr 2003
Last Updated on STN: 30 Apr 2003

L12 ANSWER 2 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:390 BIOSIS
DN PREV200300000390
TI The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
AU Jacques, P.; Moens, G. [Reprint Author]; Desombere, I.; Dewijngaert, J.; Leroux-Roels, G.; Wettendorff, M.; Thoelen, S.
CS Interdisciplinaire Dienst voor het Welzijn, IDEWE, Leuven, Belgium
guido.moens@idewe.be
SO Vaccine, (1 November 2002) Vol. 20, No. 31-32, pp. 3644-3649. print.
ISSN: 0264-410X (ISSN print).
DT Article
LA English
ED Entered STN: 18 Dec 2002
Last Updated on STN: 18 Dec 2002

L12 ANSWER 3 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:582887 BIOSIS
DN PREV200200582887
TI Combined hepatitis and herpesvirus antigen compositions.
AU Stephenne, Jean [Inventor, Reprint author]; Wettendorff, Martine Anne Cecile [Inventor]
CS Rixensart, Belgium
ASSIGNEE: SmithKline Beecham Biologicals S.A., Rixensart, Belgium
PI US 6451320 September 17, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 17, 2002) Vol. 1262, No. 3. http://www.uspto.gov/web/menu/patdata.html. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 13 Nov 2002
Last Updated on STN: 13 Nov 2002

L12 ANSWER 4 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:385622 BIOSIS
DN PREV200200385622
TI Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/ASO4, a hepatitis B vaccine with a novel adjuvant.
AU Desombere, Isabelle; Van Der Wielen, Marie; Van Damme, Pierre; Stoffel, Michel; De Clercq, Norbert; Goilav, Christian; Leroux-Roels, Geert [Reprint author]
CS Centre for Vaccinology, Ghent University Hospital, De Pintelaan 185, 9000,

Ghent, Belgium
geert.lerouxroels@rug.ac.be
SO Vaccine, (7 June, 2002) Vol. 20, No. 19-20, pp. 2597-2602. print.
CODEN: VACCDE. ISSN: 0264-410X.
DT Article
LA English
ED Entered STN: 17 Jul 2002
Last Updated on STN: 17 Jul 2002

L12 ANSWER 5 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:314082 BIOSIS
DN PREV200200314082
TI Adjuvant compositions for vaccines.
AU Boon, Thierry [Inventor, Reprint author]; Silla, Silvia [Inventor]; Uyttenhove, Catherine [Inventor]
CS Brussels, Belgium
ASSIGNEE: SmithKline Beecham Biologicals s.a., Rixensart, Belgium
PI US 6375945 April 23, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 23, 2002) Vol. 1257, No. 4. http://www.uspto.gov/web/menu/patdata.html. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 29 May 2002
Last Updated on STN: 29 May 2002

L12 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:93059 BIOSIS
DN PREV200000093059
TI A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
AU McCormack, S. [Reprint author]; Tilzey, A.; Carmichael, A.; Gotch, F.; Kepple, J.; Newberry, A.; Jones, G.; Lister, S.; Beddows, S.; Cheingsong, R.; Rees, A.; Babiker, A.; Banatvala, J.; Bruck, C.; Darbyshire, J.; Tyrrell, D.; Van Hoecke, C.; Weber, J.
CS HIV Division, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
SO Vaccine, (Jan., 2000) Vol. 18, No. 13, pp. 1166-1177. print.
CODEN: VACCDE. ISSN: 0264-410X.
DT Article
LA English
ED Entered STN: 10 Mar 2000
Last Updated on STN: 3 Jan 2002

L12 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:346722 BIOSIS
DN PREV199900346722
TI The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
AU Moore, Anne; McCarthy, Leone; Mills, Kingston H. G. [Reprint author]
CS Infection and Immunity Group, Department of Biology, National University of Ireland, Maynooth, Co. Kildare, Ireland
SO Vaccine, (June 4, 1999) Vol. 17, No. 20-21, pp. 2517-2527. print.
CODEN: VACCDE. ISSN: 0264-410X.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

```
d his

     (FILE 'HOME' ENTERED AT 08:31:48 ON 03 DEC 2004)

     FILE 'MEDLINE' ENTERED AT 08:31:56 ON 03 DEC 2004
L1           638 S HPV-16 AND HPV-18
L2             9 S L1 AND VLP
                 E WETTENDORFF/AU
L3            11 S E5
L4             0 S 3DMPL
L5             5 S 3D MPL
L6             0 S L5 AND PAPILLOMA
L7            14 S L1 AND  VIRUS-LIKE PARTICLES
L8             0 S ADJUVANT AND L7
L9             0 S ALUMINIUM AND L7

     FILE 'BIOSIS' ENTERED AT 08:43:29 ON 03 DEC 2004
L10           14 S L1 AND  VIRUS-LIKE PARTICLES
L11            0 S L10 AND 3D MPL
L12            7 S  3D MPL
```